Hikma Pharmaceuticals PLC
HKMPY · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $1,658,000 | $1,558,000 | $1,569,000 | $1,436,493 |
| % Growth | 6.4% | -0.7% | 9.2% | – |
| Cost of Goods Sold | $933,000 | $899,000 | $813,000 | $813,484 |
| Gross Profit | $725,000 | $609,800 | $756,000 | $623,010 |
| % Margin | 43.7% | 39.1% | 48.2% | 43.4% |
| R&D Expenses | $73,000 | $79,195 | $61,000 | $84,325 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $278,000 | $295,991 | $280,000 | $414,678 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $115,000 | $22,815 | $64,000 | -$992 |
| Operating Expenses | $466,000 | $398,000 | $405,000 | $498,011 |
| Operating Income | $259,000 | $234,615 | $351,000 | $124,999 |
| % Margin | 15.6% | 15.1% | 22.4% | 8.7% |
| Other Income/Exp. Net | $36,000 | -$94,000 | -$64,000 | -$46,627 |
| Pre-Tax Income | $295,000 | $167,000 | $287,000 | $78,372 |
| Tax Expense | $55,000 | $33,658 | $59,000 | $17,857 |
| Net Income | $238,000 | $131,661 | $226,000 | $58,531 |
| % Margin | 14.4% | 8.5% | 14.4% | 4.1% |
| EPS | 2.16 | 1.2 | 2.04 | 0.54 |
| % Growth | 80% | -41.2% | 277.8% | – |
| EPS Diluted | 2.14 | 1.18 | 2.02 | 0.52 |
| Weighted Avg Shares Out | 111,215 | 110,316 | 111,881 | 111,369 |
| Weighted Avg Shares Out Dil | 111,215 | 111,519 | 111,881 | 111,369 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,034 | $3,960 | $4,000 | $3,968 |
| Interest Expense | $40,344 | $43,557 | $44,000 | $42,658 |
| Depreciation & Amortization | $102,000 | $99,983 | $96,000 | $94,245 |
| EBITDA | $476,000 | $308,860 | $427,000 | $214,284 |
| % Margin | 28.7% | 19.8% | 27.2% | 14.9% |